Navigation Links
Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
Date:3/11/2008

BERKELEY, Calif., March 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT), today announced that it will release fourth quarter and full year financial results for 2007 after the market closes on Thursday, March 13, 2008. Nile management will host a conference call and live webcast to discuss these financial results and provide an update on each of its development programs at 4:30 p.m. ET, 1:30 p.m. PT that afternoon.

Interested investors may participate in the conference call by dialing 877-548-7906 (domestic) or +1-719-325-4883 (international). Participants may also access both the live and archived webcast of the conference call from the homepage and the investor relations section of Nile's website at http://www.nilethera.com. The webcast will remain available on the company's website until the next quarterly conference call.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Contact:

Daron Evans

Chief Financial Officer

Nile Therapeutics, Inc.

510-281-7700

info@nilethera.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
2. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
5. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
6. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
7. ExonHit Therapeutics - 2007 Financial Results
8. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
9. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
10. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
11. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... of the interesting and challenging endeavors as the ... highly impervious properties to the foreign substances. Ocular ... possibility of self medication and minimal use of ... molecular weight drugs and provides specific targeting within ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... , Aug. 21, 2014  BioSpecifics Technologies ... company developing first in class collagenase-based products marketed ... CCH) in the U.S. and XIAPEX ® ... results from a randomized, double-blind Phase 2a study ... or edematous fibrosclerotic panniculopathy. The results showed that ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... N.Y., Jan. 31 Mr. Donald Fresne, ... that the company has recently,obtained from Harvard ... cover certain technologies related to cancer therapy ... developed jointly,by scientists in the Laboratory for ...
... VCs face more competition from private ... equity and hedge ... their investments to the greentech and biotech industries in the,coming year, ... a recent survey by the U.S. audit, tax and advisory,firm KPMG ...
... 31 Schering-Plough,Corporation (NYSE: SGP ) today ... has accepted the Peg-IFN (peginterferon alfa-2b),supplemental Biologics License ... status for the adjuvant treatment of patients with,Stage ... agency,in the fall of 2007., The Priority ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... by an international standards process, will be available soon ... invited review published in the OnlineFirst version of ... official journal of the American Society for Parenteral and ... the occurrence of misconnection that can be harmful and ... used to join medical devices, components, and accessories to ...
(Date:8/21/2014)... University have developed a novel and versatile modeling strategy ... creating new materials as well as for studying polyelectrolytes, ... us to model much larger and more complex polyelectrolyte ... Nan Li, lead author of a paper on the ... of Materials Science and Engineering. "This is a big ...
Breaking Biology News(10 mins):Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... In 2007, researchers of the Max Planck Institute ... in exploratory behaviour in great tits. Birds with a ... (DRD4 gene) showed stronger novelty seeking and exploration behaviour ... tested and found in a lab-raised group of birds. ...
... , Some animals, it seems, are going on a ... these are reactions to rapidly rising temperatures due to ... Aviv University,s Department of Zoology, who has been measuring ... areas where climate change is most extreme. , Changes ...
... with anorexia nervosa, paradoxically, have strikingly high levels of fat ... Their findings, based on MRI imaging of the knees of ... same age, appear in the February issue of the ... that an emaciated young woman with almost no subcutaneous fat ...
Cached Biology News:Great tits: birds with character 2Animals cope with climate change at the dinner table 2Anorexics found to have excess fat-- in their bone marrow 2
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The thermal printer, 120 V, is used to record fluorescence data acquired with the VersaFluor fluorometry systems. The printer includes a cable and power adaptor....
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... iCycler thermal cycler with 384-well reaction module ... applications. It is equipped with an interchangeable, ... features algorithm temperature monitoring and control and ... sample volumes. It includes the iCycler base ...
Biology Products: